Barry J. Simon
CIK 1647994 · See remarks · last filed 2026-10-06
Barry J. Simon is a corporate insider who has filed 41 SEC Form 4 insider transactions across 4 companies since 2015. The most recent filing shows the insider sold $268.8K of IBRX on Oct 6, 2026. Across all open-market trades the lifetime net is −$17.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $21.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 210
CARDIFF-BY-THE-SEA, CA 92007
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IBRX | Director | 2,777,788 | $7.81 | $21.69M | -$6.43M | 15 | 2026-10-06 |
| Viracta Therapeutics, Inc. (VIRX) Delisted | Director | — | $0.01 | — | $0 | 4 | 2024-06-24 |
| ImmunityBio, Inc. (NK) Delisted | See remarks | 3,213,783 | — | — | -$11.36M | 15 | 2021-02-08 |
| CUE | Director | — | $18.45 | — | $0 | 4 | 2021-01-06 |
Recent Filings
41 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-06 | IBRX | Sell (S) | −25,000 | -$268.8K | EDGAR |
| 2026-10-05 | IBRX | Notice (144) | −560,000 | -$7.66M | EDGAR |
| 2026-06-26 | IBRX | Sell (S) | −25,000 | -$196.9K | EDGAR |
| 2026-06-05 | IBRX | Sell (S) | −23,033 | -$165.3K | EDGAR |
| 2026-06-04 | IBRX | Notice (144) | −268,033 | -$2.95M | EDGAR |
| 2026-02-26 | IBRX | Sell (S) | −75,000 | -$900.8K | EDGAR |
| 2026-02-24 | IBRX | Mixed | −165,783 | -$1.84M | EDGAR |
| 2026-01-21 | IBRX | Sell (S) | −151,967 | -$1.09M | EDGAR |
| 2026-01-20 | IBRX | Notice (144) | −571,967 | -$5.91M | EDGAR |
| 2025-02-25 | IBRX | Mixed | +9,790 | -$18.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.